MedPath

Impact of carbohydrate and its sources on BMI, visceral fat and non-alcoholic fatty liver in patients with type 2 diabetes

Not Applicable
Recruiting
Conditions
type 2 diabetes
Registration Number
JPRN-UMIN000038314
Lead Sponsor
Haimoto Clinic
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

Taking any type of oral hypoglycemic agent, insulin or steroid hormone from 3 months before baseline that would impact HbA1c levels; following strict carbohydrate restriction at baseline based on commercial diet therapies such as the Atkins diet; serum creatinine levels greater than 2.0 mg/dl, ketoacidosis, soft drink ketosis, cancer or decompensatory liver cirrhosis and alcoholic fatty liver disease.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
BMI and visceral fat by CT and CT value in the liver and spleen, macronutrients and carbohydrate sources based on dietary records at baseline and 6 months, and the association of changes in carbohydrate sources with changes in the above parameters.
Secondary Outcome Measures
NameTimeMethod
Insulin, HOMA-IR and serum lipid profile at baseline and 6 months later
© Copyright 2025. All Rights Reserved by MedPath